<DOC>
	<DOCNO>NCT03050398</DOCNO>
	<brief_summary>This study allow collection tumor tissue sample well understand relevant mutation mechanisms responsible resistance treatment .</brief_summary>
	<brief_title>A Companion Sample Collection Protocol Support Discovery Breast Cancer Aberrations With Treatment CDK4/6 Therapy/LEE011/Ribociclib</brief_title>
	<detailed_description>This protocol sub-protocol interventional study . Because main study interventional , study approve FDA interventional study . It stand alone without parent study . The site receive diagnostic information patient come study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Written informed consent must obtain prior baseline/screening procedure . Patients eligible companion sample collection protocol sample collection protocol must meet inclusion CLEE011A2404 . Patients eligible companion sample collection protocol must meet exclusion criterion CLEE011A2404 study , addition following : Patients without either fresh archival tumor tissue accessible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>HR-positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>LEE011</keyword>
	<keyword>ribociclib</keyword>
	<keyword>letrozole</keyword>
	<keyword>femara</keyword>
	<keyword>CDK</keyword>
	<keyword>CDK4</keyword>
	<keyword>CDK6</keyword>
	<keyword>CDK4/6</keyword>
	<keyword>CDK4/6 inhibitor</keyword>
	<keyword>Phase III</keyword>
	<keyword>Phase IIIb</keyword>
	<keyword>ER-positive</keyword>
	<keyword>PR-positive</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Premenopausal</keyword>
	<keyword>Men</keyword>
</DOC>